Prostate cancer is the leading life-threatening malignancy in American men, and novel mechanisms and therapeutic approaches can lead to reduce the morbidity and the mortality of prostate cancer. I have obtained extensive and intensive training on molecular biology and prostate cancer research using both cultured cells and animal models in Dr. Pier Paolo Pandolfi’s laboratory at Memorial Sloan-Kettering Cancer Center and Beth Israel Deaconess Medical Center/Harvard University. My research focuses on dysregulated signaling pathways in prostate cancer. My expertise and contributions to cancer research are demonstrated by my publications in several high-impact journals including Nature, Nature Genetics, Cell and Science Signaling etc. I laid the groundwork on PTEN-loss induced cellular senescence in vivo and its implication as a novel anticancer mechanism to suppress cancer progression. As PI and Co-investigator on several projects funded by my university, DoD and NIH, I have made very important discoveries on Pten-loss dysregulated pathways in prostate cancer including Castration Resistant Prostate Cancer, and projects have produced several peer-reviewed publications. In addition, I have successfully administered these research projects from training people, budget plan, and progress reports to publications. More importantly, I am fully aware of the challenges and importance of generating a realistic plan and keeping frequent communication among project members. I have established strong collaborations with investigators from other institutions in the US and other countries on prostate cancer research.